Viking Therapeutics, Inc. (VKTX)

NASDAQ: VKTX · IEX Real-Time Price · USD

67.52

+0.52 (0.77%)

At close: May 20, 2024, 4:00 PM

67.71

+0.19 (0.29%)

After-hours: May 20, 2024, 5:41 PM EDT

Viking Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Selling, General & Admin	37.02	16.12	10.7	10.73	9.13	Upgrade
Research & Development	63.81	54.23	44.98	31.93	23.56	Upgrade
Operating Expenses	100.83	70.36	55.68	42.66	32.69	Upgrade
Operating Income	-100.83	-70.36	-55.68	-42.66	-32.69	Upgrade
Other Expense / Income	-14.93	-1.49	-0.69	-3.17	-6.91	Upgrade
Pretax Income	-85.9	-68.87	-54.99	-39.5	-25.78	Upgrade
Net Income	-85.9	-68.87	-54.99	-39.5	-25.78	Upgrade
Shares Outstanding (Basic)	94	77	77	73	72	Upgrade
Shares Outstanding (Diluted)	94	77	77	73	72	Upgrade
Shares Change	22.79%	-0.47%	6.34%	0.89%	24.97%	Upgrade
EPS (Basic)	-0.91	-0.90	-0.71	-0.54	-0.36	Upgrade
EPS (Diluted)	-0.91	-0.90	-0.71	-0.54	-0.36	Upgrade
Free Cash Flow	-73.38	-48.4	-47.59	-21.78	-24.75	Upgrade
Free Cash Flow Per Share	-0.78	-0.63	-0.62	-0.30	-0.34	Upgrade
EBITDA	-85.6	-68.58	-54.69	-39.22	-25.52	Upgrade
Depreciation & Amortization	0.29	0.29	0.3	0.28	0.26	Upgrade
EBIT	-85.9	-68.87	-54.99	-39.5	-25.78	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).